A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL

This study is testing a combination of two drugs — acalabrutinib and obinutuzumab — as a first treatment for Chinese patients with chronic lymphocytic leukemia (CLL), a slow-growing type of blood cancer. Both drugs target cancer cells in different ways and together may be more effective than older treatment options. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of CLL that requires treatment - You have never been treated for CLL before (prior local radiotherapy is allowed) - Your overall health is adequate (ECOG 0-2) with no recent significant decline - Your blood counts, kidney, and liver function meet required levels - You are able to swallow capsules and tablets **You may NOT be eligible if...** - You have previously received any systemic treatment for CLL - You are HIV positive or have active hepatitis B or C - You have had a stroke or bleeding in the brain in the past 6 months - You have a bleeding disorder such as hemophilia - You are taking blood thinners like warfarin - You need proton pump inhibitors (like omeprazole) that cannot be stopped - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.